Literature DB >> 21951076

Postoperative inotrope and vasopressor use following CABG: outcome data from the CAPS-care study.

Judson B Williams1, Adrian F Hernandez, Shuang Li, Rachel S Dokholyan, Sean M O'Brien, Peter K Smith, T Bruce Ferguson, Eric D Peterson.   

Abstract

BACKGROUND/AIM: Limited clinical data exist to guide practice patterns and evidence-based use of inotropes and vasopressors following coronary artery bypass grafting (CABG).
METHODS: Contemporary Analysis of Perioperative Cardiovascular Surgical Care (CAPS-Care) collected detailed perioperative data from 2390 CABG patients between 2004 and 2005 at 55 U.S. hospitals. High-risk elective or urgent CABG patients were eligible for inclusion. We stratified participating hospitals into high, medium, and low tertiles of inotrope use. Hospital-level outcomes were compared before and after risk adjustment for baseline characteristics.
RESULTS: Hospital-level risk-adjusted rates of any inotrope/vasopressor use varied from 100% to 35%. Hospitals in the highest tertile of use had more patients with mitral regurgitation compared to medium- or low-use hospitals (p < 0.001), more previous cardiovascular interventions (p = 0.002), longer cardiopulmonary bypass (p < 0.001), longer cross-clamp times (p < 0.001), and required more transfusions (p = 0.001). Despite these differences, unadjusted outcomes were similar between high-, medium-, and low-use hospitals for operative mortality (4.5% vs. 5.3% vs. 5.2%; p = 0.702), 30-day mortality (4.1% vs. 4.6% vs. 5.0%; p = 0.690), postoperative renal failure (7.2% vs. 9.2% vs. 6.6%; p = 0.142), atrial fibrillation (23.0% vs. 27.2% vs. 25.6%; p = 0.106), and acute limb ischemia (0.6% vs. 0.5% vs. 0.5%; p = 0.945). These similar outcomes persisted after risk adjustment: adjusted OR = 0.97 (95% CI [0.94, 1.00], p = 0.086) for operative mortality and adjusted OR = 1.00 (95% CI [0.96, 1.04], p = 0.974) for postoperative renal failure.
CONCLUSION: While considerable variability is present among hospitals in inotrope use following CABG, observational comparison of outcomes did not distinguish a superior pattern; thus, randomized prospective data are needed to better guide clinical practice.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951076      PMCID: PMC3677728          DOI: 10.1111/j.1540-8191.2011.01301.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  17 in total

1.  Alabama coronary artery bypass grafting project: results from phase II of a statewide quality improvement initiative.

Authors:  William L Holman; Monique Sansom; Catarina I Kiefe; Eric D Peterson; Steve G Hubbard; James F Delong; Richard M Allman
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

2.  Validity of the Society of Thoracic Surgeons National Adult Cardiac Surgery Database.

Authors:  Karl F Welke; T Bruce Ferguson; Laura P Coombs; Rachel S Dokholyan; Cindy J Murray; Mary A Schrader; Eric D Peterson
Journal:  Ann Thorac Surg       Date:  2004-04       Impact factor: 4.330

3.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

Authors:  Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

4.  Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice.

Authors:  Judson B Williams; Elizabeth R Delong; Eric D Peterson; Rachel S Dokholyan; Fang-Shu Ou; T Bruce Ferguson
Journal:  Circulation       Date:  2010-12-20       Impact factor: 29.690

5.  Factors that predict the use of positive inotropic drug support after cardiac valve surgery.

Authors:  J F Butterworth; C Legault; R L Royster; J W Hammon
Journal:  Anesth Analg       Date:  1998-03       Impact factor: 5.108

6.  Effects of milrinone versus epinephrine on grafted internal mammary artery flow after cardiopulmonary bypass.

Authors:  E B Lobato; F Urdaneta; T D Martin; N Gravenstein
Journal:  J Cardiothorac Vasc Anesth       Date:  2000-02       Impact factor: 2.628

7.  Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.

Authors:  Timothy M Hoffman; Gil Wernovsky; Andrew M Atz; Thomas J Kulik; David P Nelson; Anthony C Chang; James M Bailey; Akbar Akbary; John F Kocsis; Raymond Kaczmarek; Thomas L Spray; David L Wessel
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690

8.  Preoperative and intraoperative predictors of inotropic support and long-term outcome in patients having coronary artery bypass grafting.

Authors:  R L Royster; J F Butterworth; D S Prough; W E Johnston; J L Thomas; P E Hogan; L D Case; G P Gravlee
Journal:  Anesth Analg       Date:  1991-06       Impact factor: 5.108

Review 9.  Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.

Authors:  Michael Gillies; Rinaldo Bellomo; Laurie Doolan; Brian Buxton
Journal:  Crit Care       Date:  2004-12-16       Impact factor: 9.097

10.  French multicentre survey on the use of inotropes after cardiac surgery.

Authors:  Olivier Bastien; Benoit Vallet
Journal:  Crit Care       Date:  2005-02-23       Impact factor: 9.097

View more
  8 in total

1.  Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry.

Authors:  Benjamin A Steinberg; Yue Zhao; Xia He; Adrian F Hernandez; David A Fullerton; Kevin L Thomas; Roger Mills; Winslow Klaskala; Eric D Peterson; Jonathan P Piccini
Journal:  Clin Cardiol       Date:  2013-12-18       Impact factor: 2.882

2.  On-Pump Beating/Non-Beating CABG in Stable Angina Have Similar Outcomes.

Authors:  Victor Dayan; Juan Jose Paganini; Alvaro Marichal; Daniel Brusich
Journal:  Braz J Cardiovasc Surg       Date:  2018 Mar-Apr

3.  Surgical coronary revascularization in patients with COVID-19; complications and outcomes: A retrospective cohort study.

Authors:  Aryan Ayati; Kaveh Hosseini; Alireza Hadizadeh; Arash Jalali; Masoumeh Lotfi-Tokaldany; Nesa Milan; Jamshid Bagheri; Seyed Hossein Ahmadi Tafti
Journal:  Health Sci Rep       Date:  2022-08-10

4.  A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery.

Authors:  T G Coulson; L F Miles; A Serpa Neto; D Pilcher; L Weinberg; G Landoni; A Zarbock; R Bellomo
Journal:  Anaesthesia       Date:  2022-09       Impact factor: 12.893

5.  Use of Vasoactive Medications after Cardiac Surgery in the United States.

Authors:  Emily A Vail; Meng-Shiou Shieh; Penelope S Pekow; Hayley B Gershengorn; Allan J Walkey; Peter K Lindenauer; Hannah Wunsch
Journal:  Ann Am Thorac Soc       Date:  2021-01

6.  Early troponin T and prediction of potentially correctable in-hospital complications after coronary artery bypass grafting surgery.

Authors:  Volkhard Göber; Andreas Hohl; Brigitta Gahl; Florian Dick; Verena Eigenmann; Thierry P Carrel; Hendrik T Tevaearai
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

7.  Catecholamine and volume therapy for cardiac surgery in Germany--results from a postal survey.

Authors:  Christoph Sponholz; Christoph Schelenz; Konrad Reinhart; Uwe Schirmer; Sebastian N Stehr
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

8.  Inotropic and Mechanical Support of Critically Ill Patient after Cardiac Surgery.

Authors:  Suad Keranovic; Edis Salihovic; Dzenana Zrnanovic; Maja Prelic; Azra Piric; Tarik Kikanovic
Journal:  Med Arch       Date:  2020-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.